Some studies showed that the activated YAP could bypass K-RAS to promote cell proliferation and survival in several tumor types, and that YAP could also promote resistance to RAF-targeted and MEK-targeted cancer therapies46–48. This evidence concerns the gene MAP2K7 and neoplasm.